Latest News

Vesalius Biocapital III Fund closes at €120 million

© fotolia.com/sdecoret


by TG

Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m.

The fund includes commitments of €30m from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA. Vesalius Biocapital III has already executed three investments. These include investments in Forendo, a clinical stage drug development company focusing on novel treatments in women’s health; Mecuris, a Munich-based medtech developing an easy-to-use online platform for customizable and 3D-printed orthotics and prosthetics; and SWORD Health, a tech-enabled provider of physical therapy, pairing its AI-powered digital therapists with human clinical teams to recover patients faster and better.

Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health with the goal of investing in 10 to 15 companies over the lifetime of the fund.

bit bio restarts with new management

Cambridge-based cell reprogramming specialist Elpis Biomed will be re-started under the new name bit bio with a new management and an extended...

ADC Therapeutics set to go public

The number of shares to be offered and the price range for the proposed offering have still to be determined. Despite an internal review conducted...

Gut bacterial enzyme keeps inflammation away

In studies in human cells, Victor Duarte and colleagues from University of Grenoble, found broad-spectrum antimicrobial activity of a compound...

Patient's organoids predict response to chemotherapy

The organoid-based test, developed by the group of Emile Voest at Netherland’s Cancer Institute in Amsterdam, in a prospective clinical trial...

Qiagen/Illumina: Earthquake in NGS IVD market

The announcement of the 15-year partnership of next generation sequencing (NGS) market leader Illumina and QIAGEN came after Illumina cut its 2019...

Novo secures Dicerna’s RNAi liver assets

Under the deal, which includes potential treatments for NASH, orphan liver diseases, obesity and diabetes, Dicerna could theoretically earn...

UniQure looking to raise US$200m

The Amsterdam-based company announced that it had commenced an underwritten public offering of US$200m of its ordinary shares. uniQure also intends...